Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657184 | 1.00 | TGFBR1 (1.00) | TGFBR1EGFRERBB3CA12CA1 | |
| SCHEMBL29429424 | 1.00 | TGFBR1 (1.00) | TGFBR1EGFRERBB3CA12CA1 | |
| SCHEMBL4174543 | 0.90 | TGFBR1 (0.82) | TGFBR1 | |
| SCHEMBL3953868 | 0.89 | TGFBR1 (0.79) | TGFBR1ROCK1 | |
| SCHEMBL4172942 | 0.88 | TGFBR1 (0.79) | TGFBR1 | |
| SCHEMBL4168353 | 0.87 | TGFBR1 (0.77) | TGFBR1CCNA2CDK2 | |
| SCHEMBL3953297 | 0.86 | TGFBR1 (0.75) | TGFBR1EGFRERBB3CA1CA2 | |
| SCHEMBL3946083 | 0.85 | TGFBR1 (0.73) | TGFBR1CA12CA1CA2 | |
| SCHEMBL4183440 | 0.85 | TGFBR1 (0.73) | TGFBR1 | |
| SCHEMBL3948134 | 0.84 | TGFBR1 (0.72) | TGFBR1EGFRERBB3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | claimed |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | claimed |
| EP-3690022-B1 | CELL CULTURE MEDIUM FOR CULTURING ORGANOID, CULTURE METHOD, AND ORGANOID | UNIV KEIO (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20240385180-A1 | PRODUCTION OF ORGANOID DERIVED FROM CTC OF SMALL CELL LUNG CANCER PATIENT, AND IGF1R INHIBITOR AS A MOLECULAR TARGET DRUG FOR SMALL CELL LUNG CANCER | KEIO UNIVERSITY (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4403186-A1 | PRODUCTION OF ORGANOID DERIVED FROM CTC OF SMALL CELL LUNG CANCER PATIENT, AND IGF1R INHIBITOR AS A MOLECULAR TARGET DRUG FOR SMALL CELL LUNG CANCER | Keio University (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024071212-A1 | DRUG FOR CULTURING ORGANOID IN ABSENCE OF EXTRACELLULAR MATRIX | 慶應義塾 | 2024-04-04 | — | — | WO | disclosed |
| EP-3418376-B1 | CELL CULTURE MEDIUM, CULTURE METHOD, AND ORGANOID | UNIV KEIO (JP) | 2024-03-13 | — | — | EP | disclosed |
| EP-3460042-B1 | CELL CULTURE MEDIUM FOR CULTURING ORGANOID, CULTURE METHOD, AND ORGANOID | UNIV KEIO (JP) | 2024-02-21 | — | — | EP | disclosed |
| EP-3418376-A1 | CELL CULTURE MEDIUM, CULTURE METHOD, AND ORGANOID | Keio University (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | TGFBR1 106/4885EGFR 26/4885ERBB3 8/4885 |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | TGFBR1 1324/4885EGFR 106/4885ERBB3 263/4885 |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885EGFR 60/4885ERBB3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.